doi: 10.14202/vetworld.2017.1329-1332
Share this article on [Facebook] [LinkedIn]
Article history: Received: 05-08-2017, Accepted: 16-10-2017, Published online: 12-11-2017
Corresponding author: Abel Villa Mancera
E-mail: abel.villa@gmail.com
Citation: Reynoso Palomar A, Mena Aguilar G, Cruz Garcia M, Pastelin Rojas C, Villa Mancera A (2017) Production of aldosterone in cardiac tissues of healthy dogs and with dilated myocardiopathy, Veterinary World, 10(11): 1329 1332.Background and Aim: Aldosterone is a hormone, belonging to the group of mineralocorticoids, mainly synthesized in the adrenal cortex, basically its function is to regulate blood pressure and sodium potassium levels in the body; high levels of this hormone have harmful effects in the organism and mainly in the heart in chronic form. Dilated cardiomyopathy is a progressive disease of heart muscle that is characterized by ventricular chamber enlargement and contractile dysfunction, is one of the most common cardiac conditions in dogs of medium and large breeds. The aim of the study was to determine and quantify if a dog's cardiac cells possess the capacity to synthesize aldosterone, as well as, the differences that appear between a healthy heart and with dilated myocardiopathy (DMC).
Materials and Methods: Cardiac tissues were used from six healthy dogs and six with DMC. Enzyme linked immunosorbent assay was performed to determine if the dog's heart cells synthesized this mineralocorticoid in a similar way to rat, rabbit, and human tissues, as well as quantitative differences between the healthy heart and DMC.
Results: In healthy dog hearts, aldosterone values were 62.5 pG for both the atria and right ventricle and 125 pG for the left ventricle. As for dog hearts' with DMC, results were 125 pG in all four cavities.
Conclusion: Both the healthy and DMC dog hearts produce aldosterone in all four cavities, observing that production increases in the atria and right ventricle of those hearts with DMC, as an intrinsic mechanism of cardiac remodeling.
Keywords: cardiac insufficiency, dog heart, enzyme linked immunosorbent assay, mineralocorticoids.
1. Alonso, J.A.M. and Ramirez, E.Y. (2007) Manual Practico de Electrocardiografia en Peque-os Animales. Elsevier Espa-a.
2. Chetboul, V., Serres, F., Tissier, R., Lefebvre, H.P., Sampedrano, C.C., Gouni, V. and Pouchelon, J. (2009) Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J. Vet. Int. Med., 23(5): 984-994. [Crossref] [PubMed]
3. Oyama, M.A. and Levy, R.J. (2010) Insights into serotonin signaling mechanisms associated with canine degenerative mitral valve disease. J. Vet. Int. Med., 24(1): 27-36. [Crossref] [PubMed]
4. McMahon, E.G. (2001) Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol., 1(2): 190-196. [Crossref]
5. Seferovic, P.M., Pelliccia, F., Zivkovic, I., Ristic, A., Lalic, N., Seferovic, J. and Rosano, G. (2015) Mineralocorticoid receptor antagonists, a class beyond spironolactone--focus on the special pharmacologic properties of eplerenone. Int. J. Cardiol., 200: 3-7. [Crossref] [PubMed]
6. Munoz-Durango, N., Vecchiola, A., Gonzalez-Gomez, L.M., Simon, F., Riedel, C.A., Fardella, C.E. and Kalergis, A.M. (2015) Modulation of immunity and inflammation by the mineralocorticoid receptor and aldosterone. Biomed. Res. Int., 2015: 652738. [Crossref] [PubMed] [PMC]
7. Young, M.J. and Funder, J.W. (2002) Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J. Hypertens., 20(8): 1465-1468. [Crossref]
8. Luo, G., Lu, F., Qiao, L., Chen, X., Li, G. and Zhang, Y. (2016) Discovery of potential inhibitors of aldosterone synthase from Chinese herbs using pharmacophore modeling, molecular docking, and molecular dynamics simulation studies. Biomed. Res., 2016: 4182595. [Crossref]
9. Verdugo, F.J., Montellano, F.A., Carreno, J.E. and Marusic, E.T. (2014) Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage. Rev. Med. Chil., 142(1): 61-71. [Crossref] [PubMed]
10. Reynoso, P.A.R., Rodriguez, B.M., Villa, M.A.E. and Mucha, C.J. (2017) Expression and biochemical characteristics of two different aldosterone receptors in both healthy and dilated cardiomyopathy dog heart tissue. Vet. Res. Commun., 41(1): 9-14. [Crossref] [PubMed]
11. Patricio-Martinez, P., Villa-Mancera, A., Issac-Salgado, A.C., Rodriguez, C.J.C., Mucha, C. and Reynoso-Palomar, A.R. (2014) Immunohistochemical expression of aldosterone receptors in cardiac tissues of healthy dogs. Exp. Clin. Cardiol., 20(8): 2160-2164.
12. Ovaert, P., Elliott, J., Bernay, F., Guillot, E. and Bardon, T. (2010) Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure. J. Vet. Pharmacol. Ther., 33(2): 109-117. [Crossref] [PubMed]
13. Delcayre, C., Silvestre, J.S., Garnier, A., Oubenaissa, A., Cailmail, S., Tatara, E. and Robert, V. (2000) Cardiac aldosterone production and ventricular remodeling. Kidney Int., 57(4): 1346-1351. [Crossref] [PubMed]
14. Kayes-Wandover, K.M. and White, P.C. (2000) Steroidogenic enzyme gene expression in the human heart. J. Clin. Endocrinol. Metab., 85(7): 2519-2525. [Crossref]